JP2019527200A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527200A5 JP2019527200A5 JP2018566552A JP2018566552A JP2019527200A5 JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5 JP 2018566552 A JP2018566552 A JP 2018566552A JP 2018566552 A JP2018566552 A JP 2018566552A JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- scil
- monomer subunit
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353478P | 2016-06-22 | 2016-06-22 | |
| US62/353,478 | 2016-06-22 | ||
| PCT/US2017/038747 WO2018005226A2 (en) | 2016-06-22 | 2017-06-22 | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527200A JP2019527200A (ja) | 2019-09-26 |
| JP2019527200A5 true JP2019527200A5 (enExample) | 2020-07-30 |
| JP7084881B2 JP7084881B2 (ja) | 2022-06-15 |
Family
ID=60674961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566552A Expired - Fee Related JP7084881B2 (ja) | 2016-06-22 | 2017-06-22 | Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10335459B2 (enExample) |
| EP (1) | EP3474884A4 (enExample) |
| JP (1) | JP7084881B2 (enExample) |
| AU (2) | AU2017291321B2 (enExample) |
| CA (1) | CA3026393C (enExample) |
| WO (1) | WO2018005226A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011302645B2 (en) | 2010-09-15 | 2015-02-26 | Applied Molecular Transport, Llc | Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| EP3139965B1 (en) | 2014-05-07 | 2021-09-29 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| EP3233920B1 (en) * | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| AU2019240370B2 (en) * | 2018-03-23 | 2024-03-07 | Gavish-Galilee Bio Applications Ltd. | Genetically reprogrammed Tregs expressing membrane-bound IL-10 |
| ES2911075T3 (es) | 2018-11-07 | 2022-05-17 | Applied Molecular Transport Inc | Constructos de administración para transcitosis y métodos relacionados |
| CN113811549A (zh) * | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| JP2023520508A (ja) * | 2020-04-03 | 2023-05-17 | ベイラー カレッジ オブ メディスン | ＴＮＦαシグナル伝達は治療の標的とされ得る腫瘍促進性炎症の引き金を引く |
| KR20230009430A (ko) * | 2020-05-12 | 2023-01-17 | 리제너론 파아마슈티컬스, 인크. | 신규 il10 효능제 및 그의 사용 방법 |
| JP2023527359A (ja) * | 2020-05-28 | 2023-06-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 改変インターロイキン－１０ポリペプチド及びその使用 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2024094755A1 (en) * | 2022-11-02 | 2024-05-10 | Synerkine Pharma B.V. | Engineered immunocytokines, fusion polypeptides, and il10 polypeptides |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| WO2024144336A1 (ko) * | 2022-12-30 | 2024-07-04 | 주식회사 프로젠 | 신규 이중 특이성 융합단백질 및 그의 용도 |
| KR20260034078A (ko) * | 2023-06-02 | 2026-03-10 | 신테카인, 인크. | 융합된 il10 폴리펩티드 |
| TW202613172A (zh) * | 2024-05-31 | 2026-04-01 | 大陸商江蘇先聲生物製藥有限公司 | 抗cdh17抗體、綴合物及其應用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| EP1151012A4 (en) | 1998-11-19 | 2003-01-08 | Smithkline Beecham Corp | ANTAGONIST ANTIBODIES OF RHAMM |
| US6428985B1 (en) * | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| WO2004044006A1 (en) * | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| WO2008140595A2 (en) | 2006-12-01 | 2008-11-20 | President And Fellows Of Harvard College | Synthetic trivalent haptens, complexes thereof, and uses therefor |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| RU2578420C2 (ru) | 2010-05-10 | 2016-03-27 | Эсенд Байофармасьютикалз Пти Лтд | Иммуностимулирующие и вакцинные композиции |
| CN101962413B (zh) * | 2010-09-21 | 2013-03-13 | 中国科学技术大学 | 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用 |
| KR101333958B1 (ko) | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| EP2457579A1 (en) | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9346872B2 (en) * | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| JP2016526014A (ja) * | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０組成物及びその使用 |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
-
2017
- 2017-06-22 WO PCT/US2017/038747 patent/WO2018005226A2/en not_active Ceased
- 2017-06-22 JP JP2018566552A patent/JP7084881B2/ja not_active Expired - Fee Related
- 2017-06-22 US US15/630,341 patent/US10335459B2/en active Active
- 2017-06-22 CA CA3026393A patent/CA3026393C/en active Active
- 2017-06-22 AU AU2017291321A patent/AU2017291321B2/en not_active Ceased
- 2017-06-22 EP EP17820960.7A patent/EP3474884A4/en not_active Withdrawn
-
2019
- 2019-05-16 US US16/414,223 patent/US11534480B2/en active Active
-
2020
- 2020-07-03 AU AU2020204457A patent/AU2020204457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018171063A5 (enExample) | ||
| JP2009524429A5 (enExample) | ||
| JP2017512063A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| JP2018510622A5 (enExample) | ||
| JP2015525217A5 (enExample) | ||
| JP2019535268A5 (ja) | アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物 | |
| JP2013520426A5 (enExample) | ||
| JP2008514618A5 (enExample) | ||
| JP2022513653A5 (enExample) | ||
| JP2010519252A5 (enExample) | ||
| IL294059A (en) | Mutant rsv f protein and its use | |
| JP2019033754A5 (enExample) | ||
| JP2014224126A5 (enExample) | ||
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| JP2014510518A5 (enExample) | ||
| JP2019531093A5 (enExample) | ||
| JP2014509851A5 (enExample) | ||
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih | |
| JP2019163253A5 (enExample) | ||
| JP2017536098A5 (enExample) | ||
| JP2012532601A5 (enExample) | ||
| JP2015504052A5 (enExample) | ||
| JP2014525439A5 (enExample) | ||
| JP2017509335A5 (enExample) |